ClinicalTrials.gg
Active, not recruitingNCT05797610IMAGINATIONUpdated Oct 28, 2026

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

A Phase 3 interventional study of Sefaxersen (RO7434656) and Placebo in Primary IgA Nephropathy, sponsored by Hoffmann-La Roche. Active, not recruiting at 162 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
459
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
9th of 109
459 · median 84
Started
2023
with 10 others
Phase 3
22 of 127
9 open now
Primary completion
2028-05
later than 47 of 72 live
Registered
61st of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 9th largest by enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2023, is one of 22 in phase 3, reaches primary completion later than 47 of the 72 other live ones, and was the 61st registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, \& pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary IgAN, as evidenced by a kidney performed within 10 years prior to or during screening, without known secondary cause
  • Treatment with maximum tolerated doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for at least 90 days immediately prior to screening, and without an intent to modify the dose during the study, except for interruptions due to illness (not greater than 7 consecutive days), unless the potential participant is intolerant to these medications
  • Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1 gram per gram (g/g) or urine protein excretion ≥ 1 gram per day (g/day) (with UPCR ≥ 0.8 g/g), all measured from a 24-hour urine collection during screening
  • ≥ 20 mL/min/1.73 m\^2, as calculated by the 2021 CKD-EPI creatinine equation (Inker et al. 2021a)
  • Vaccination against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae according to national vaccination recommendations
  • Female participants of must use adequate

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 weeks after the final dose of sefaxersen
  • Histopathologic or other evidence of another glomerular disease
  • Presence of ≥ 50% crescents on kidney , sustained doubling of serum creatinine within 3 months prior to screening, or rapidly progressive glomerulonephritis in the opinion of the investigator
  • History of kidney transplantation
  • (HbA1c) ≥ 6.5% or a clinical diagnosis of diabetes mellitus of any type
  • Systolic blood pressure >140 millimetre of mercury (mmHg) or diastolic blood pressure >90 mmHg from the average of two measurements performed at least 1 minute apart during screening
  • Initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors within 16 weeks prior to screening or during screening
  • Initiation of endothelin receptor antagonists within 90 days prior to screening or during screening
  • Initiation of mineralocorticoid receptor antagonists or non-dihydropyridine calcium channel blockers within 90 days prior to screening or during screening
  • Use of herbal therapies within 90 days prior to or during screening
  • Treatment with therapy within 28 days prior to screening or 5.5 drug-elimination half-lives of that investigational product prior to screening
  • Treatment with an investigational therapy planned during the treatment period
  • Previous treatment with sefaxersen
  • Treatment with oral or intravenous (IV) with a dose equivalent to ≥ 7.5 milligrams per day (mg/day) of prednisone for 7 days or equivalent to ≥ 5 mg/day of prednisone for 14 days within 90 days prior to screening
  • Treatment with corticosteroids with systemic effects during screening
  • Treatment with a systemic calcineurin inhibitor within 2 months prior to screening or during screening
  • Treatment with anti-CD20 therapy within 9 months of screening or during screening
  • Treatment with other systemic agents within 6 months of randomization including, but not limited to, complement inhibitors, alkylating agents (e.g., cyclophosphamide or chlorambucil), azathioprine, or mycophenolate
  • Planned major procedure or major surgery during screening or the study
  • Substance abuse within 12 months prior to screening or during screening
  • Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study
  • History of within \< 5 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Usage of Glucagon-like Peptide-1 (GLP-1)-based therapy (i.e., GLP-1 mono-agonists, GLP-1/GIP dual agonists, etc.) within 90 days prior to screening or during screening, or intent to initiate during the study period
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
459 participants (actual)

Study arms

  • Experimental
    Sefaxersen (RO7434656)

    Participants will receive subcutaneous (SC) doses of sefaxersen (RO7434656) on Days 1, 15, and 29 followed by once every 4 weeks (Q4W) until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first. The common-close timepoint is defined as the data cut-off date for the primary analysis.

    Drug: Sefaxersen (RO7434656)

  • Placebo comparator
    Placebo

    Participants will receive SC doses of sefaxersen (RO7434656) matching placebo on Days 1, 15, and 29 followed by once Q4W until Week 105. Participants may be eligible to switch to open-label treatment after Week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first. The common-close timepoint is defined as the data cut-off date for the primary analysis.

    Drug: Placebo

Interventions

  • Sefaxersen (RO7434656) will be administered as SC injection per schedule as specified in the protocol.

    Also known as: Sefaxersen

  • DrugPlacebo

    Matching placebo will be administered as SC injection per schedule as specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Urine Protein-to-Creatinine Ratio (UPCR) at Week 37

    UPCR will be assessed in urine sampled over 24 hours.

    Time frame: Baseline, Week 37

Secondary outcomes

  1. Estimated Glomerular Filtration Rate (eGFR) Slope at Week 105 from Baseline

    eGFR will be calculated using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.

    Time frame: Baseline, Week 105

  2. Time to the Composite Kidney Failure Endpoint

    Time to the composite kidney failure endpoint is defined as receipt of kidney transplantation, need for kidney replacement therapy, or a sustained decline in eGFR of ≥ 30% or a sustained eGFR \< 15 milliliters/minutes/1.73m\^2 (mL/min/1.73m\^ 2) over at least 4 weeks (both eGFR criteria requires two consecutive central laboratory eGFR values meeting criteria ≥ 4 weeks apart), whichever occurs first.

    Time frame: Up to approximately 36 months

  3. Percentage of Participants Achieving Hematuria Resolution at Week 37

    Time frame: At Week 37

  4. Change From Baseline in Fatigue at Week 105

    Fatigue will be assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue subscale (FACIT-F). The FACIT-F Scale is a 13-item scale used to measure self-reported fatigue. Items are assessed on a 5-point Likert scale, with responses ranging from 0 for "not at all" to 4 for "very much". Relevant items are reverse scored, and all items are summed up to create a total score ranging from 0 to 52, with higher scores indicative of better functioning (i.e., less fatigue).

    Time frame: Baseline, Week 105

  5. Percentage of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 36 months

  6. Plasma Concentration of Sefaxersen

    Time frame: Up to approximately 36 months

Other outcomes

  1. Change From Baseline in Symptoms and Health-Related Quality of Life at Week 105 as Assessed Using the RAND Kidney Disease and Quality of Life 36-Item (KDQOL-36) Short Form

    The RAND KDQOL-36 is an abbreviated questionnaire that combines the generic and disease-specific components to assess participant's health-related quality of life. This 36-item questionnaire includes the RAND 12, Version 1 (12 items) and 3 disease-related domains, symptoms/problems (12 items), burden of kidney disease (4 items), and effects of kidney disease (8 items). It uses a recall of 4 weeks, and items are assessed on 3- to 5-point Likert scales or with a dichotomous response option. Higher score indicates better health. The raw scores are transformed linearly to a range of 0 to 100, with higher scores indicating better health.

    Time frame: Baseline, Week 105

07

Study locations

162 sites

Showing the first 100 of 162 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Sato T, Fukase H, Ishida T, Karasawa A. A First-in-Japanese Phase 1, Double-Blind, Placebo-Controlled, Parallel-Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants. Clin Pharmacol Drug Dev. 2026 Sep;15(9):e70097. doi: 10.1002/cpdd.70097. PubMed 42713733 ↗
  • Tekendo-Ngongang C, Gleeson JG, Mignon L. Treating the Untreatable: Antisense Oligonucleotides as an Individualized Therapy for Rare Genetic Kidney Diseases. J Am Soc Nephrol. 2024 Dec 1;35(12):1774-1777. doi: 10.1681/ASN.0000000532. Epub 2024 Sep 27. No abstract available. PubMed 39331470 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for May 2028, 57 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 57 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2026 → May 2028 and completion Mar 2029 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 4, 2023
StartActual
Aug 8, 2023
Primary completionEst.
May 25, 2028was Aug 2026
CompletionEst.
Aug 31, 2029was Mar 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 17 sites removed
Show site
  • UCLA University of California Los Angeles · Los Angeles, United States
Show 17 removed
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica · Los Angeles, United States
  • Tokyo Medical University Ibaraki Medical Center · Inashiki-Gun, Japan
  • Iwate Medical University Hospital · Numakunai, Japan
  • Okayama University Hospital · Okayama-Shi Kita-Ku, Japan
  • University of the Ryukyus Hospital · Okinawa, Japan
  • Saitama Medical University Hospital · Saitama, Japan
  • Jichi Medical University Hospital · Tochigi, Japan
  • Tokushima University Hospital · Tokushima, Japan
  • Hopital Henri Mondor · Créteil, France
  • Hopital Bichat - Claude Bernard AP-HP · Paris, France
  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte · Berlin, Germany
  • Fondazione Policlinico Universitario A Gemelli · Rome, Italy
  • Kyoto City Hospital · Nakagyo-ku, Japan
  • 4. Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ · Wroclaw, Poland
  • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
  • Hospital Ribera Polusa · Lugo, Spain
  • Hospital Universitario 12 De Octubre · Madrid, Spain
across 2 updates, Oct 5, 2026 – Oct 28, 2026
Primary completion
Aug 31, 2026→May 25, 2028
Oct 5, 2026
Study completion
Mar 31, 2029→Aug 31, 2029
Oct 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42713733 ↗
Oct 5, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange From Baseline in Fatigue at Week 105: how it is measured was reworded
Oct 5, 2026
Show all 2 updates
  1. Oct 28, 2026
    9 sites removed
    Show 9 removed
    • Hopital Henri Mondor · Créteil, France
    • Hopital Bichat - Claude Bernard AP-HP · Paris, France
    • Charite Universitaetsmedizin Berlin - Campus Charite Mitte · Berlin, Germany
    • Fondazione Policlinico Universitario A Gemelli · Rome, Italy
    • Kyoto City Hospital · Nakagyo-ku, Japan
    • 4. Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ · Wroclaw, Poland
    • C.H. Regional Reina Sofia - PPDS · Córdoba, Spain
    • Hospital Ribera Polusa · Lugo, Spain
    • Hospital Universitario 12 De Octubre · Madrid, Spain
    + 1 other change: verification date
  2. Oct 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42713733 ↗
    1 site added, 8 sites removed
    Show site
    • UCLA University of California Los Angeles · Los Angeles, United States
    Show 8 removed
    • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica · Los Angeles, United States
    • Tokyo Medical University Ibaraki Medical Center · Inashiki-Gun, Japan
    • Iwate Medical University Hospital · Numakunai, Japan
    • Okayama University Hospital · Okayama-Shi Kita-Ku, Japan
    • University of the Ryukyus Hospital · Okinawa, Japan
    • Saitama Medical University Hospital · Saitama, Japan
    • Jichi Medical University Hospital · Tochigi, Japan
    • Tokushima University Hospital · Tokushima, Japan
    Primary completion Aug 31, 2026→May 25, 2028
    Study completion Mar 31, 2029→Aug 31, 2029
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange From Baseline in Fatigue at Week 105: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05797610
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 4, 2023
Start date
Aug 8, 2023
Primary completion
May 25, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sefaxersen

Start the discussion